Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
EyePoint, Inc.
Report date March 30, 2024 · Filed April 02, 2024
Section 16 reporting ended · disclosed 2024-04-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 67,080 |
Ending reported balance
After 2024-03-30 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2024-03-30 · Exercise / conversion · Acquired 5,834 · Balance 48,056 Row 2 · 2024-03-30 · Exercise / conversion · Acquired 30,570 · Balance 78,626 Row 3 · 2024-03-30 · Exercise / conversion · Acquired 14,000 · Balance 92,626 Row 4 · 2024-03-30 · Tax withholding · Disposed 15,493 · Balance 77,133 F1: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units Row 5 · 2024-03-30 · Tax withholding · Disposed 2,957 · Balance 74,176 F1: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units Row 6 · 2024-03-30 · Tax withholding · Disposed 7,096 · Balance 67,080 F1: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2024-03-30 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-03-30 · Exercise / conversion · Disposed 30,570 · Balance 0 F2: The restricted stock units will vest in three ratable annual installments beginning January 6, 2024. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2024-03-30 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-03-30 · Exercise / conversion · Disposed 5,834 · Balance 0 F3: The restricted stock units will vest in three ratable annual installments beginning February 9, 2023. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2024-03-30 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2024-03-30 · Exercise / conversion · Disposed 14,000 · Balance 0 F4: The restricted stock units will vest in three ratable annual installments beginning January 5, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units
F2: The restricted stock units will vest in three ratable annual installments beginning January 6, 2024.
F3: The restricted stock units will vest in three ratable annual installments beginning February 9, 2023.
F4: The restricted stock units will vest in three ratable annual installments beginning January 5, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 30, 2024 Filed Apr 2, 2024 21:27 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionRestricted Stock Units · Derivative | 14,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-003193 · primarydocument.xml · derivative · entry 9 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning January 5, 2025. F4 · derivative.expiration_date: The restricted stock units will vest in three ratable annual installments beginning January 5, 2025. Read SEC document |
| March 30, 2024 Filed Apr 2, 2024 21:27 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionRestricted Stock Units · Derivative | 5,834 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-003193 · primarydocument.xml · derivative · entry 8 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,834 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning February 9, 2023. F3 · derivative.expiration_date: The restricted stock units will vest in three ratable annual installments beginning February 9, 2023. Read SEC document |
| March 30, 2024 Filed Apr 2, 2024 21:27 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionRestricted Stock Units · Derivative | 30,570 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-003193 · primarydocument.xml · derivative · entry 7 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,570 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning January 6, 2024. F2 · derivative.expiration_date: The restricted stock units will vest in three ratable annual installments beginning January 6, 2024. Read SEC document |
| March 30, 2024 Filed Apr 2, 2024 21:27 UTC | EyePoint, Inc. EYPT · Entity 5702 | Tax withholdingCommon Stock | 7,096 | $20.67 | $146,674.32 |
DisclosureSEC source: 0001562180-24-003193 · primarydocument.xml · nonDerivative · entry 6 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,080 F1 · kind: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units Read SEC document |
| March 30, 2024 Filed Apr 2, 2024 21:27 UTC | EyePoint, Inc. EYPT · Entity 5702 | Tax withholdingCommon Stock | 2,957 | $20.67 | $61,121.19 |
DisclosureSEC source: 0001562180-24-003193 · primarydocument.xml · nonDerivative · entry 5 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,176 F1 · kind: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units Read SEC document |
| March 30, 2024 Filed Apr 2, 2024 21:27 UTC | EyePoint, Inc. EYPT · Entity 5702 | Tax withholdingCommon Stock | 15,493 | $20.67 | $320,240.31 |
DisclosureSEC source: 0001562180-24-003193 · primarydocument.xml · nonDerivative · entry 4 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,133 F1 · kind: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units Read SEC document |
| March 30, 2024 Filed Apr 2, 2024 21:27 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-003193 · primarydocument.xml · nonDerivative · entry 3 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,626 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 30, 2024 Filed Apr 2, 2024 21:27 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 30,570 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-003193 · primarydocument.xml · nonDerivative · entry 2 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,626 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 30, 2024 Filed Apr 2, 2024 21:27 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 5,834 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-003193 · primarydocument.xml · nonDerivative · entry 1 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,056 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 22:39 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionRestricted Stock Units · Derivative | 5,833 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-001293 · primarydocument.xml · derivative · entry 6 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,834 Underlying: Common Stock · 5,833 shares Expires 2032-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning February 9, 2023. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 22:39 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionRestricted Stock Units · Derivative | 4,967 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-001293 · primarydocument.xml · derivative · entry 5 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,967 shares Expires 2031-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning February 9, 2022. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 22:39 UTC | EyePoint, Inc. EYPT · Entity 5702 | Tax withholdingCommon Stock | 2,565 | $28.80 | $73,872.00 |
DisclosureSEC source: 0001562180-24-001293 · primarydocument.xml · nonDerivative · entry 4 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,222 F1 · kind: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 22:39 UTC | EyePoint, Inc. EYPT · Entity 5702 | Tax withholdingCommon Stock | 2,518 | $28.80 | $72,518.40 |
DisclosureSEC source: 0001562180-24-001293 · primarydocument.xml · nonDerivative · entry 3 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,787 F1 · kind: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 22:39 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 5,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-001293 · primarydocument.xml · nonDerivative · entry 2 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,305 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 22:39 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 4,967 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-001293 · primarydocument.xml · nonDerivative · entry 1 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,472 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2024 Filed Jan 30, 2024 21:53 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,609 | $0.00 Strike: $12.90 | $0.00 |
DisclosureSEC source: 0001562180-24-000808 · primarydocument.xml · derivative · entry 9 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,026 Underlying: Common Stock · 15,609 shares Expires 2030-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which began March 28, 2020 Read SEC document |
| January 26, 2024 Filed Jan 30, 2024 21:53 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionStock Option (Right to Buy) · Derivative | 33,665 | $0.00 Strike: $13.13 | $0.00 |
DisclosureSEC source: 0001562180-24-000808 · primarydocument.xml · derivative · entry 8 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,588 Underlying: Common Stock · 33,665 shares Expires 2031-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at February 9th, 2022 and the remainder ratably, on a monthly basis, over the remaining three years. Read SEC document |
| January 26, 2024 Filed Jan 30, 2024 21:53 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionStock Option (Right to Buy) · Derivative | 51 | $0.00 Strike: $13.13 | $0.00 |
DisclosureSEC source: 0001562180-24-000808 · primarydocument.xml · derivative · entry 7 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,253 Underlying: Common Stock · 51 shares Expires 2031-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at February 9th, 2022 and the remainder ratably, on a monthly basis, over the remaining three years. Read SEC document |
| January 26, 2024 Filed Jan 30, 2024 21:53 UTC | EyePoint, Inc. EYPT · Entity 5702 | SaleCommon Stock | 33,665 | $25.77 | $867,671.61 |
DisclosureSEC source: 0001562180-24-000808 · primarydocument.xml · nonDerivative · entry 6 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,505 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $26.62. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| January 26, 2024 Filed Jan 30, 2024 21:53 UTC | EyePoint, Inc. EYPT · Entity 5702 | SaleCommon Stock | 15,609 | $25.41 | $396,571.62 |
DisclosureSEC source: 0001562180-24-000808 · primarydocument.xml · nonDerivative · entry 5 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,170 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $25.88. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| January 26, 2024 Filed Jan 30, 2024 21:53 UTC | EyePoint, Inc. EYPT · Entity 5702 | SaleCommon Stock | 51 | $25.41 | $1,295.74 |
DisclosureSEC source: 0001562180-24-000808 · primarydocument.xml · nonDerivative · entry 4 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,779 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $25.88. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| January 26, 2024 Filed Jan 30, 2024 21:53 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 33,665 | $13.13 | $442,021.45 |
DisclosureSEC source: 0001562180-24-000808 · primarydocument.xml · nonDerivative · entry 3 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2024 Filed Jan 30, 2024 21:53 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 51 | $13.13 | $669.63 |
DisclosureSEC source: 0001562180-24-000808 · primarydocument.xml · nonDerivative · entry 2 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,165 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2024 Filed Jan 30, 2024 21:53 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 15,609 | $12.90 | $201,356.10 |
DisclosureSEC source: 0001562180-24-000808 · primarydocument.xml · nonDerivative · entry 1 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,114 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 25, 2024 Filed Jan 29, 2024 22:51 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionStock Option (Right to Buy) · Derivative | 300 | $0.00 Strike: $12.90 | $0.00 |
DisclosureSEC source: 0001562180-24-000784 · primarydocument.xml · derivative · entry 6 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,635 Underlying: Common Stock · 300 shares Expires 2030-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which began March 28, 2020 Read SEC document |
| January 25, 2024 Filed Jan 29, 2024 22:51 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionStock Option (Right to Buy) · Derivative | 300 | $0.00 Strike: $13.13 | $0.00 |
DisclosureSEC source: 0001562180-24-000784 · primarydocument.xml · derivative · entry 5 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,304 Underlying: Common Stock · 300 shares Expires 2031-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at February 9th, 2022 and the remainder ratably, on a monthly basis, over the remaining three years. Read SEC document |
| January 25, 2024 Filed Jan 29, 2024 22:51 UTC | EyePoint, Inc. EYPT · Entity 5702 | SaleCommon Stock | 300 | $25.00 | $7,500.00 |
DisclosureSEC source: 0001562180-24-000784 · primarydocument.xml · nonDerivative · entry 4 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,505 Read SEC document |
| January 25, 2024 Filed Jan 29, 2024 22:51 UTC | EyePoint, Inc. EYPT · Entity 5702 | SaleCommon Stock | 300 | $25.00 | $7,500.00 |
DisclosureSEC source: 0001562180-24-000784 · primarydocument.xml · nonDerivative · entry 3 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,805 Read SEC document |
| January 25, 2024 Filed Jan 29, 2024 22:51 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 300 | $12.90 | $3,870.00 |
DisclosureSEC source: 0001562180-24-000784 · primarydocument.xml · nonDerivative · entry 2 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,105 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 25, 2024 Filed Jan 29, 2024 22:51 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 300 | $13.13 | $3,939.00 |
DisclosureSEC source: 0001562180-24-000784 · primarydocument.xml · nonDerivative · entry 1 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,805 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 24, 2024 Filed Jan 25, 2024 23:26 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,651 | $0.00 Strike: $12.90 | $0.00 |
DisclosureSEC source: 0001562180-24-000637 · primarydocument.xml · derivative · entry 12 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,935 Underlying: Common Stock · 5,651 shares Expires 2030-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which began March 28, 2020 Read SEC document |
| January 24, 2024 Filed Jan 25, 2024 23:26 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,600 | $0.00 Strike: $13.13 | $0.00 |
DisclosureSEC source: 0001562180-24-000637 · primarydocument.xml · derivative · entry 11 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,604 Underlying: Common Stock · 5,600 shares Expires 2031-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at February 9th, 2021 and the remainder ratably, on a monthly basis, over the remaining three years. Read SEC document |
| January 24, 2024 Filed Jan 25, 2024 23:26 UTC | EyePoint, Inc. EYPT · Entity 5702 | SaleCommon Stock | 5,651 | $25.02 | $141,363.16 |
DisclosureSEC source: 0001562180-24-000637 · primarydocument.xml · nonDerivative · entry 8 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,505 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $25.14. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| January 24, 2024 Filed Jan 25, 2024 23:26 UTC | EyePoint, Inc. EYPT · Entity 5702 | SaleCommon Stock | 5,600 | $25.01 | $140,052.08 |
DisclosureSEC source: 0001562180-24-000637 · primarydocument.xml · nonDerivative · entry 7 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,156 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $25.14. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| January 24, 2024 Filed Jan 25, 2024 23:26 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 5,600 | $13.13 | $73,528.00 |
DisclosureSEC source: 0001562180-24-000637 · primarydocument.xml · nonDerivative · entry 6 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,756 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 24, 2024 Filed Jan 25, 2024 23:26 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 5,651 | $12.90 | $72,897.90 |
DisclosureSEC source: 0001562180-24-000637 · primarydocument.xml · nonDerivative · entry 5 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,156 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 23:26 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,039 | $0.00 Strike: $12.90 | $0.00 |
DisclosureSEC source: 0001562180-24-000637 · primarydocument.xml · derivative · entry 10 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,586 Underlying: Common Stock · 2,039 shares Expires 2030-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which began March 28, 2020 Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 23:26 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,096 | $0.00 Strike: $13.13 | $0.00 |
DisclosureSEC source: 0001562180-24-000637 · primarydocument.xml · derivative · entry 9 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,204 Underlying: Common Stock · 3,096 shares Expires 2031-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at February 9th, 2021 and the remainder ratably, on a monthly basis, over the remaining three years. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 23:26 UTC | EyePoint, Inc. EYPT · Entity 5702 | SaleCommon Stock | 3,096 | $25.00 | $77,400.00 |
DisclosureSEC source: 0001562180-24-000637 · primarydocument.xml · nonDerivative · entry 4 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,505 Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 23:26 UTC | EyePoint, Inc. EYPT · Entity 5702 | SaleCommon Stock | 2,039 | $25.00 | $50,975.00 |
DisclosureSEC source: 0001562180-24-000637 · primarydocument.xml · nonDerivative · entry 3 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,601 Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 23:26 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 2,039 | $12.90 | $26,303.10 |
DisclosureSEC source: 0001562180-24-000637 · primarydocument.xml · nonDerivative · entry 2 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,640 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 23:26 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 3,096 | $13.13 | $40,650.48 |
DisclosureSEC source: 0001562180-24-000637 · primarydocument.xml · nonDerivative · entry 1 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,601 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 08, 2024 Filed Jan 10, 2024 21:53 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionStock Option (Right to Buy) · Derivative | 22,913 | $0.00 Strike: $3.26 | $0.00 |
DisclosureSEC source: 0001562180-24-000414 · primarydocument.xml · derivative · entry 3 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,742 Underlying: Common Stock · 22,913 shares Expires 2033-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at January 6th, 2024 and the remainder ratably, on a monthly basis, over the remaining three years. Read SEC document |
| January 08, 2024 Filed Jan 10, 2024 21:53 UTC | EyePoint, Inc. EYPT · Entity 5702 | SaleCommon Stock | 22,913 | $21.13 | $484,124.19 |
DisclosureSEC source: 0001562180-24-000414 · primarydocument.xml · nonDerivative · entry 2 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,505 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.54 to $21.94. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 08, 2024 Filed Jan 10, 2024 21:53 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 22,913 | $3.26 | $74,696.38 |
DisclosureSEC source: 0001562180-24-000414 · primarydocument.xml · nonDerivative · entry 1 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,418 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2024 Filed Jan 10, 2024 02:28 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionRestricted Stock Units · Derivative | 15,285 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-000403 · primarydocument.xml · derivative · entry 5 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,570 Underlying: Common Stock · 15,285 shares Expires 2033-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The restricted stock units vests in three ratable annual installments beginning January 6, 2024. Read SEC document |
| January 06, 2024 Filed Jan 10, 2024 02:28 UTC | EyePoint, Inc. EYPT · Entity 5702 | Tax withholdingCommon Stock | 4,487 | $20.40 | $91,534.80 |
DisclosureSEC source: 0001562180-24-000403 · primarydocument.xml · nonDerivative · entry 2 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,505 F1 · kind: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units Read SEC document |
| January 06, 2024 Filed Jan 10, 2024 02:28 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 15,285 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-000403 · primarydocument.xml · nonDerivative · entry 1 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,992 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 05, 2024 Filed Jan 10, 2024 02:28 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 42,000 | $0.00 Strike: $20.40 | $0.00 |
DisclosureSEC source: 0001562180-24-000403 · primarydocument.xml · derivative · entry 4 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2034-01-04 F3 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at January 5th, 2025 and the remainder ratably, on a monthly basis, over the remaining three years. Read SEC document |
| January 05, 2024 Filed Jan 10, 2024 02:28 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantRestricted Stock Units · Derivative | 21,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-000403 · primarydocument.xml · derivative · entry 3 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2034-01-05 F2 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning January 5, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.